Immunotherapy-Chemo combo aims to outperform standard chemoradiation in esophageal cancer
NCT ID NCT07699185
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This clinical trial compares two approaches for treating locally advanced esophageal squamous cell carcinoma before surgery. One group receives the immunotherapy drug cardonilizumab combined with chemotherapy, while the other receives standard chemoradiotherapy. The goal is to see which treatment leads to a higher rate of complete tumor disappearance at the time of surgery. The study involves about 336 participants and will also track survival, side effects, and surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cardonilizumab (an immunotherapy drug) combined with chemotherapy
- What this could lead to
- If successful, this approach could offer a more effective, less toxic pre-surgery treatment for locally advanced esophageal cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a Phase 2 trial, so results are preliminary. The immunotherapy may cause immune-related side effects, and it might not prove superior to the current standard of care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji hospital
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
- Smart T-Cell engager aims to outsmart tumors in first human test